Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
BioCentury This Week
00:00
How Kite Pharma Is Building a Successful Cancer Franchise
Gilead has four products but really only three are commercially meaningful the two CAR-T programs in Tordelvi. They want 20 approved products by 2030 that's going to take some work and I think that's probably going to have to come outside of their existing or it'll have to be complemented with more BD from them so there's definitely more building to come.
Transcript
Play full episode
